Is the Wegovy 0.25mg Dose Effective for Weight Loss?

Why the first dose is built around adjustment, not results

Starting any GLP-1 medicine at full therapeutic strength would, for most people, mean a rough first few weeks. Nausea, loose stools and stomach discomfort are the most common early side effects of semaglutide, and they are strongly dose-dependent. The 0.25mg starting dose was chosen because it sits low enough to minimise those effects while your gut, and the appetite-signalling pathways in your brain, begin to adapt to the medicine.

This is not a compromise or a cautious workaround. It is how the medicine is licensed and how it performed in the STEP 1 trial, which enrolled nearly 2,000 adults and is the evidence base behind Wegovy's UK approval. The NHS medicines page for semaglutide sets out the same titration logic: you move through the schedule, and weight change builds progressively as the dose rises.

Think of it like this: if you keep your 0.25mg pen in the fridge door and pull it out every Monday morning, you are not yet at the part of treatment designed to shift weight. You are at the part designed to make the next part tolerable. That framing matters, because stopping at this stage based on an absence of results would mean stopping before the medicine has had any real opportunity to work.

For a fuller picture of how the treatment builds over time, the Wegovy weight-loss effectiveness page covers what the trial data shows at maintenance doses.

When to genuinely question whether it is working

The more useful question is not whether 0.25mg is effective (it is not intended to be) but what "not working" looks like at any dose, and when that becomes a clinical decision rather than a timing issue.

NICE guidance recommends that if a patient has not achieved at least 5% weight loss after six months on the maintenance dose, continuing the medicine should be reviewed. The operative word is maintenance. Six months at 0.25mg tells you almost nothing about the medicine's effect on your weight. Six months at 2.4mg, with the titration completed, tells you a great deal about whether Wegovy is delivering meaningful results for you.

There are people for whom the side-effect burden at higher doses means titration has to slow down or pause. There are people whose prescriber determines they should stay at an intermediate dose for longer. All of that is normal and individual. What matters is that these decisions happen through clinical oversight, not because someone drew their own conclusion from a few weeks at the lowest dose.

The factors that affect how well Wegovy works page goes into more depth on adherence, timing and lifestyle variables, all of which interact with dose.

What the titration schedule looks like in practice

Wegovy's licensed UK titration runs: 0.25mg for four weeks, then 0.5mg, then 1.0mg, then 1.7mg, then 2.4mg, each step held for roughly four weeks. Your prescriber may adjust that pace based on how you are tolerating each step. Rushing titration does not tend to improve results; it mainly increases the chance of side effects that make people want to stop.

The most common side effects across the programme are gastrointestinal: nausea is the most frequently reported, followed by constipation, diarrhoea, vomiting and stomach discomfort. These effects are typically at their strongest after a dose increase and settle for most people within a couple of weeks. They do not usually persist at full intensity once the body has adjusted to the new level.

Side effects that are more serious are less common. Pancreatitis is a known but infrequent risk: severe stomach pain that spreads to the back, with or without vomiting, needs prompt medical attention. If you experience that, do not wait for your next review. The MHRA's Yellow Card scheme lets you report any suspected side effects from a prescription medicine directly at yellowcard.mhra.gov.uk.

For a broader overview of how semaglutide works at the mechanism level, the semaglutide information page explains the GLP-1 pathway in plain language.

The clinical decision you are actually making

If you are on 0.25mg and wondering whether Wegovy is the right treatment for you, the real question is not about this dose. It is about whether you are set up to complete the full titration with proper clinical support, and whether 2.4mg is the right endpoint for your situation.

A prescriber can look at your health history, current medicines, and any conditions that might interact with treatment, and give you an honest answer about what to expect. That is a different conversation from reading a trial statistic and trying to map it onto your first few weeks.

The timeline for Wegovy weight loss page sets realistic expectations for how long meaningful change typically takes. And if you want to understand how semaglutide compares against the broader picture of what is available, the most effective semaglutide doses page covers the evidence across the range.

If you are considering starting treatment through a regulated private service, nume's prescribers carry out a same-day clinical review of every consultation. There are no algorithms making that call. You can check your eligibility through a free consultation if you would like to understand what is clinically appropriate for you.